Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
PTC Therapeutics ( (PTCT) ) has shared an update.
On December 29, 2025, PTC Therapeutics, Inc. entered into a second amendment to its Amended and Restated Royalty Purchase Agreement with Royalty Pharma Investments 2019 ICAV, under which PTC sold its remaining economic interest in royalties on worldwide net sales of Roche’s Evrysdi (risdiplam) and related products. In exchange for its retained royalty stake—representing 9.5111% of the royalty before a specified 2020 royalty cap is met and 16.6666% thereafter—PTC received $240 million in upfront cash and became eligible for up to three additional $20 million payments tied to future annual royalty payment thresholds for 2027, 2028 and 2029, resulting in Royalty Pharma now owning 100% of the Evrysdi royalty stream and PTC fully monetizing this asset to bolster its cash resources but relinquishing future royalty income from the product.
The most recent analyst rating on (PTCT) stock is a Buy with a $93.00 price target. To see the full list of analyst forecasts on PTC Therapeutics stock, see the PTCT Stock Forecast page.
Spark’s Take on PTCT Stock
According to Spark, TipRanks’ AI Analyst, PTCT is a Outperform.
PTC Therapeutics’ strong earnings call and undervalued stock position are significant positives. However, financial risks due to high leverage and declining free cash flow growth temper the overall score. The technical outlook is stable, supporting a positive but cautious investment stance.
To see Spark’s full report on PTCT stock, click here.
More about PTC Therapeutics
PTC Therapeutics, Inc. is a biopharmaceutical company that generates a portion of its revenues through royalty streams tied to sales of partnered therapies, including Roche’s Evrysdi (risdiplam) for spinal muscular atrophy, under a long-standing license and collaboration agreement with Roche and the Spinal Muscular Atrophy Foundation.
Average Trading Volume: 1,520,576
Technical Sentiment Signal: Buy
Current Market Cap: $6.31B
See more insights into PTCT stock on TipRanks’ Stock Analysis page.